We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.02 | 0.14% | 14.00 | 14.13 | 13.81 | 13.92 | 8,987,437 | 23:13:35 |
By Michael Dabaie
Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food and Drug Administration approved AirDuo Digihaler Inhalation Powder.
That is a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application for information on inhaler use to people with asthma.
AirDuo Digihaler is indicated for the treatment of asthma in patients aged 12 and older.
The approval of AirDuo Digihaler is based on the review of the supplemental new drug application Teva submitted to the FDA.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 15, 2019 09:18 ET (13:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions